Project description DEENESFRITPL Extracellular vesicles as a source for microsatellite instability analysis in endometrial cancer Endometrial cancer (EC) is the most common gynaecological cancer, and there is a need for the development of efficient, early-stage EC diagnosis and treatments. Immunotherapy improves survival rates in various cancers but requires reliable biomarkers for the selection of patients. Microsatellite instability (MSI) has been identified as a biomarker candidate for immunotherapy selection. MSI evaluation requires tumour genetic material, which can be obtained from bloodstream extracellular vesicles. Funded by the Marie Skłodowska-Curie Actions programme, the EVOLVE project will focus on the development of the enrichment and analysis of extracellular vesicles from bodily fluids of EC patients to assess MSI using lab-on-chip and microfluidics methods in combination with DNA biomarkers and surface-enhanced Raman scattering technology. Show the project objective Hide the project objective Objective Endometrial cancer (EC) is the most common gynaecological cancer, and has an estimated incidence rise of more than 50% worldwide by 2040, mainly associated with increasing obesity prevalence. In 2018 alone, there were approximately 380,000 new cases and close to 90,000 deaths attributed to EC worldwide. Thus, there is a growing need for the development of better platforms for inexpensive, early stage EC diagnosis and treatments. Immunotherapy has shown a sharp increase in survival rate in various cancers, but only in a small percentage of treated patients. The lack of reliable biomarkers for the selection of this sub-group of patients is a great hindrance to its broader application in the clinical setting. However, microsatellite instability (MSI) has been shown to be a good candidate for immunotherapy selection. MSI evaluation requires genetic material from tumors, which can be found in extracellular vesicles released by EC cells to the bloodstream. “Isolation and Analysis of Extracellular Vesicles using OptofLuidics for the eValuation of Microsatellite Instability in Endometrial Cancer (EVOLVE)” is thus a project focused on the development of an integrated solution for the enrichment and analysis of extracellular vesicles from body fluids of endometrial cancer patients to assess microsatellite instability using lab-on-chip, microfluidics methods in conjunction with DNA biomarkers and surface-enhanced Raman scattering technology. Fields of science engineering and technologyother engineering and technologiesmicrotechnologylab on a chipnatural sciencesbiological sciencescell biologymedical and health sciencesclinical medicineoncologymedical and health sciencesbasic medicineimmunologyimmunotherapymedical and health scienceshealth sciencesnutritionobesity Keywords Microfluidics Raman Spectroscopy Extracellular Vesicles Endometrial Cancer Programme(s) HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme Topic(s) HORIZON-MSCA-2021-PF-01-01 - MSCA Postdoctoral Fellowships 2021 Call for proposal HORIZON-MSCA-2021-PF-01 See other projects for this call Funding Scheme MSCA-PF - MSCA-PF Coordinator LABORATORIO IBERICO INTERNACIONAL DE NANOTECNOLOGIA LIN Net EU contribution € 156 778,56 Address Avenida mestre jose veiga 4715-330 Braga Portugal See on map Region Continente Norte Cávado Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window EU contribution No data Partners (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA Spain Net EU contribution € 0,00 Address Travesa da choupana 15706 Santiago de compostela See on map Region Noroeste Galicia A Coruña Activity type Research Organisations Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding No data
